{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004740","form_type":"8-K","ticker":"EXPO","cik":"0000851520","company_name":"EXPONENT INC","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.790084+00:00","generated_at":"2026-06-13T01:40:43.788192+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Exponent Q2 rev before reimb +9.7% to $129.7M, EPS $0.50; FY guidance maintained","bullets":["Total revenues $140.2M (+7.6% YoY); revenues before reimbursements $129.7M (+9.7% YoY).","Net income $25.7M ($0.50 diluted EPS) vs $25.8M ($0.49) in Q2 2022; tax rate 29.0%.","EBITDA margin fell to 28.4% of rev before reimb from 31.4% YoY; headcount up 15%.","Engineering & sci segment rev before reimb +10% YoY; environmental & health +10% YoY.","Board declared $0.26/share quarterly dividend, payable Sept 22, record Sept 8."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004740","json":"https://secwatch.observer/filing/0001171843-23-004740.json","markdown":"https://secwatch.observer/filing/0001171843-23-004740.md","text":"https://secwatch.observer/filing/0001171843-23-004740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/851520/000117184323004740/0001171843-23-004740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/851520/000117184323004740/f8k_072723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T01:40:43.788192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ad6a94b43373e7d2fe6779347f9db2ccac42ced","claim":"EXPONENT INC reported second quarter ended June 30, 2023 results: revenue $140.2 million, net income $25.7 million, EPS $0.50 per diluted share. Guidance reaffirmed.","evidence_excerpt":"Total revenues and revenues before reimbursements for the second quarter of 2023 increased 7.6% to $140.2 million and 9.7% to $129.7 million as compared to $130.3 million and $118.2 million in the second quarter of 2022, respectively. Net income was $25.7 million, or $0.50 per diluted share, in the second quarter of 2023, as compared to $25.8 million, or $0.49 per diluted share, in the same period of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/851520/000117184323004740/0001171843-23-004740-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$140.2 million"},{"label":"Net income","value":"$25.7 million"},{"label":"EPS","value":"$0.50 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"94327e98bc3e0d8a0624e091baa6e244b6e0be78","claim":"EXPONENT INC reported first half of 2023 results: revenue $280.5 million, net income $54.9 million, EPS $1.06 per diluted share. Guidance reaffirmed.","evidence_excerpt":"Total revenues and revenues before reimbursements for the first half of 2023 increased 8.4% to $280.5 million and 9.4% to $258.4 million, respectively, as compared to $258.8 million and $236.1 million in the same period one year ago. Net income was $54.9 million, or $1.06 per diluted share, in the first half of 2023, as compared to $55.4 million, or $1.05 per diluted share, in the same period of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/851520/000117184323004740/0001171843-23-004740-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first half of 2023"},{"label":"Revenue","value":"$280.5 million"},{"label":"Net income","value":"$54.9 million"},{"label":"EPS","value":"$1.06 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}